Dr. Oh Discusses the Role of Chemotherapy in Prostate Cancer

William K. Oh, MD
Published: Tuesday, Feb 21, 2017



William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.

As new agents emerge and immunotherapies develops, many patients and some oncologists are quick to dismiss chemotherapy as a treatment option, Oh explains.

Chemotherapy has had a second life, says Oh, with the success of the STAMPEDE and CHAARTED trials in metastatic hormone-sensitive prostate cancer.

Also, there is a subset of patients, Oh suggests, who did not respond to primary androgen receptor (AR)-therapy who would be good candidates for chemotherapy, instead of a second AR-targeted therapy.
 


William K. Oh, MD, professor, Mount Sinai Hospital, discusses the current role of chemotherapy in the treatment of patients with prostate cancer.

As new agents emerge and immunotherapies develops, many patients and some oncologists are quick to dismiss chemotherapy as a treatment option, Oh explains.

Chemotherapy has had a second life, says Oh, with the success of the STAMPEDE and CHAARTED trials in metastatic hormone-sensitive prostate cancer.

Also, there is a subset of patients, Oh suggests, who did not respond to primary androgen receptor (AR)-therapy who would be good candidates for chemotherapy, instead of a second AR-targeted therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x